Piper Sandler lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $12.50 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Hold Rating Maintained for Myriad Genetics Amid Revenue Cuts and Strategic Uncertainty
- Myriad Genetics Faces Challenges Amid Prenatal Testing Growth
- Myriad Genetics downgraded to Peer Perform from Outperform at Wolfe Research
- China announces stimulus measures, Disney reports Q2 beat: Morning Buzz
- Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum